Explore

Novo Nordisk Acquires Rights to Oral Obesity Drug from Hengrui Pharma for up to $2.6 Billion

Novo Nordisk Acquires Rights to Oral Obesity Drug from Hengrui Pharma for up to $2.6 Billion

Novo Nordisk Acquires Rights to Oral Obesity Drug from Hengrui Pharma for up to $2.6 Billion

Novo Nordisk Secures €1.165 Billion Licensing Deal with Nanexa for Long-Acting Injectable Technology

Novo Nordisk Secures €1.165 Billion Licensing Deal with Nanexa for Long-Acting Injectable Technology

Novo Nordisk Secures €1.165 Billion Licensing Deal with Nanexa for Long-Acting Injectable Technology

Novo Nordisk Stock Declines 17.8% Amidst Increased Competition and Patent Expiries

Novo Nordisk Stock Declines 17.8% Amidst Increased Competition and Patent Expiries

Novo Nordisk Stock Declines 17.8% Amidst Increased Competition and Patent Expiries

Novo Nordisk's CagriSema Shows Superior Weight Loss Against Lower Dose Eli Lilly Tirzepatide in Phase 3 Trial

Novo Nordisk's CagriSema Shows Superior Weight Loss Against Lower Dose Eli Lilly Tirzepatide in Phase 3 Trial

Novo Nordisk's CagriSema Shows Superior Weight Loss Against Lower Dose Eli Lilly Tirzepatide in Phase 3 Trial

Roche Discontinues Development of Muscle-Sparing Obesity Drug Emugrobart After Disappointing Mid-Stage Results

Roche Discontinues Development of Muscle-Sparing Obesity Drug Emugrobart After Disappointing Mid-Stage Results

Roche Discontinues Development of Muscle-Sparing Obesity Drug Emugrobart After Disappointing Mid-Stage Results

Luckin Coffee Expands Internationally, Reaching 100 Singapore Stores and Eyeing Middle East

Luckin Coffee Expands Internationally, Reaching 100 Singapore Stores and Eyeing Middle East

Luckin Coffee Expands Internationally, Reaching 100 Singapore Stores and Eyeing Middle East

Iranians face soaring prices for medicine as the US blockade and sanctions hit hard

Iranians face soaring prices for medicine as the US blockade and sanctions hit hard

Medication prices are soaring in Iran and some treatments have become hard to find, leaving patients and their families scrambling as a U.S. blockade and stepped-up sanctions squeeze the country’s pharmaceuticals industry

Georgia Tech and Emory University Researchers Develop Targeted GI Delivery for mRNA Therapies and Vaccines

Georgia Tech and Emory University Researchers Develop Targeted GI Delivery for mRNA Therapies and Vaccines

Researchers at Georgia Tech and Emory University have discovered that delivering lipid nanoparticle (LNP) medicines directly to various areas of the gastrointestinal (GI) tract can precisely alter where these therapies travel in the body. This innovation opens new possibilities for mRNA therapies and vaccines by enabling more precise targeting of specific organs while limiting unwanted side effects in others. Traditionally, LNPs are delivered subcutaneously or intravenously, which can lead to drug interactions with organs like the liver, lungs, and spleen, causing side effects and limiting dosage. By using mouse models, the researchers mapped how nanoparticles traveled after microneedle injections into different parts of the GI tract, including the cheeks, stomach, and rectum. They found that this method allowed them to target organs such as the pancreas and lymph nodes more effectively, while reducing uptake in the liver, lungs, and spleen. For example, delivering glucagon-like peptide-1 (GLP-1) mRNA dose...

Representative Kevin Hern Sells Shares of Novo Nordisk A/S

Representative Kevin Hern Sells Shares of Novo Nordisk A/S

Representative Kevin Hern (Republican-Oklahoma) recently sold shares of Novo Nordisk A/S (NYSE: NVO). A filing disclosed on September 25th revealed that the Representative sold between $1,001 and $15,000 worth of Novo Nordisk A/S stock on September 10th. This transaction was made through the Representative's "KEVIN HERN TRADITIONAL IRA" account. Novo Nordisk A/S is a Denmark-based global pharmaceutical company specializing in treatments for diabetes, obesity, and other chronic diseases. Its product portfolio includes injectable and oral medicines for diabetes, such as insulin products and GLP-1 therapies like Ozempic and Rybelsus, as well as the obesity treatment Wegovy. The company also develops and markets products for rare blood disorders, growth hormone therapies, and hormone replacement treatments. Shares of NVO opened at $38.69 on Tuesday, with a market capitalization of $172.77 billion.

Gotion and Volkswagen Plan $3.67 Billion Investment in European Battery Supply Chain

Gotion and Volkswagen Plan $3.67 Billion Investment in European Battery Supply Chain

Gotion and Volkswagen Plan $3.67 Billion Investment in European Battery Supply Chain

Eli Lilly Secures Two FDA Approvals and Major Drug Discovery Alliance

Eli Lilly Secures Two FDA Approvals and Major Drug Discovery Alliance

Eli Lilly Secures Two FDA Approvals and Major Drug Discovery Alliance

Tirzepatide Activates Calorie-Burning Brown Fat, Offering New Insights for Obesity Treatment

Tirzepatide Activates Calorie-Burning Brown Fat, Offering New Insights for Obesity Treatment

A new study in mice suggests that tirzepatide, the active ingredient in drugs like Zepbound and Mounjaro, may improve metabolism by directly activating brown adipose tissue, a type of fat that specializes in burning calories. Tirzepatide is approved for weight management in adults with obesity or overweight with comorbidities, and for treating type 2 diabetes. Unlike other obesity medications, tirzepatide targets receptors for two hormonal factors, GIP and GLP-1, leading to substantial weight loss primarily by reducing food intake. Researchers, led by Marion Peyrou, investigated whether tirzepatide also produces metabolic changes beyond appetite suppression. By comparing obese mice treated with tirzepatide to those given the same amount of food without the drug, they found that tirzepatide activated brown fat, increasing its capacity to burn metabolic energy and produce beneficial molecules called batokines.